Native Human IgG protein is a Human Full Length protein with >95% purity and suitable for SDS-PAGE.. The predicted molecular weight of ab91102 native protein is 150 kDa
- Save time and ensure accurate results - use our IgG protein as an isotype control
- No cross-reaction from other immunoglobulin isotypes
View Alternative Names
Immunoglobulin heavy constant gamma 1, Ig gamma-1 chain C region, Ig gamma-1 chain C region EU, Ig gamma-1 chain C region KOL, Ig gamma-1 chain C region NIE, IGHG1
- SDS-PAGE
Unknown
SDS-PAGE - Native Human IgG protein (AB91102)
SDS-PAGE : 4-12% Bis-Tris NuPAGE gel
Lane 1. Molecular weight markers
Lane 2. 5 μg IgG (reduced/heated)
Lane 3. 10 μg IgG (reduced/heated)
Lane 4. 20 μg IgG (reduced/heated)
Lane 5. 5 μg IgG (non-reduced/no heat)
Lane 6. 10 μg IgG non-reduced/no heat)
Lane 7. 20 μg IgG non-reduced/no heat)
Reactivity data
Product details
The Native Human IgG protein ab91102 is prepared from plasma shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.
Ensure the validity of your result using our native human Immunoglobulin G (IgG) protein as a control in SDS-PAGE.
Check out our protein gel staining guide for SDS-PAGE here
Protein Determination: Extinction Coefficient (ε) 0.1% at 280 nm, 1 cm pathway = 1.36
Sequence info
Properties and storage information
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Specifications
Form
Lyophilized
General info
Function
Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed : 20176268, PubMed : 22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed : 17576170, PubMed : 20176268). Mediates IgG effector functions on monocytes triggering ADCC of virus-infected cells.
Post-translational modifications
Glycosylation on Asn-180 is required for interaction with Fc receptors and ability to activate the complement pathway.. (Microbial infection) Deglycosylation on Asn-180 by S.pyogenes EndoS or Endos2 endoglucosidases prevents interaction between immunoglobulin-gamma (IgG) and Fc receptors, impairing ability to activate the complement pathway.
Target data
Additional targets
Publications (11)
Recent publications for all applications. Explore the full list and refine your search
Journal of asthma and allergy 17:833-845 PubMed39281094
2024
Applications
Unspecified application
Species
Unspecified reactive species
Clinical cancer research : an official journal of the American Association for Cancer Research 30:1009-1021 PubMed38109209
2023
Applications
Unspecified application
Species
Unspecified reactive species
Scientific reports 13:17820 PubMed37857783
2023
Applications
Unspecified application
Species
Unspecified reactive species
Journal of human lactation : official journal of International Lactation Consultant Association 37:492-498 PubMed34297643
2021
Applications
Unspecified application
Species
Unspecified reactive species
Viruses 13: PubMed34372525
2021
Applications
Unspecified application
Species
Unspecified reactive species
F1000Research 8:1875 PubMed32201571
2019
Applications
Unspecified application
Species
Unspecified reactive species
Nanoscale 11:14010-14015 PubMed31309963
2019
Applications
Unspecified application
Species
Unspecified reactive species
Maternal health, neonatology and perinatology 5:9 PubMed31205733
2019
Applications
Unspecified application
Species
Unspecified reactive species
Oncology letters 16:3231-3240 PubMed30127919
2018
Applications
Unspecified application
Species
Unspecified reactive species
The Journal of clinical investigation 123:4809-20 PubMed24084741
2013
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com